Crohn's disease is a chronic inflammatory disorder which may affect any part of the gastrointestinal tract. Its pathogenesis is only partially understood; various environmental and host (e.g., genetic, epithelial, immune and non-immune) factors are involved, together initiating a chronic uncontrolled inflammation, which is partly due to an imbalance between pro- and anti-inflammatory cytokines, and a defective apoptosis of lamina propria T cells. Among proinflammatory cytokines, tumour necrosis factor-α (TNF-α) seems to play a central role in Crohn's disease. Over the past years, the increasing knowledge on the pathogenesis of Crohn's disease has led to the development of a number of biological agents targeting specific molecules involved in gut inflammation, including TNF-α and its receptors. This paper reviews the rationale for the use of TNF-α inhibitors in the treatment of Crohn's disease.
|Translated title of the contribution||Anti-TNF-α antibody therapy in Crohn's disease|
|Number of pages||8|
|Journal||Lege Artis Medicinae|
|Publication status||Published - Sep 1 2007|
ASJC Scopus subject areas